Cargando…
Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study)
INTRODUCTION: Non-valvular atrial fibrillation (NVAF) is known as a robust risk factor for stroke. Recent reports have suggested a risk of dementia with NVAF, but much remains unknown regarding the relationship between this mechanism and the potential protective effects of novel anticoagulants (dire...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254414/ https://www.ncbi.nlm.nih.gov/pubmed/30478106 http://dx.doi.org/10.1136/bmjopen-2018-021759 |
_version_ | 1783373710262009856 |
---|---|
author | Saji, Naoki Sakurai, Takashi Ito, Kengo Tomimoto, Hidekazu Kitagawa, Kazuo Miwa, Kaori Tanaka, Yuji Kozaki, Koichi Kario, Kazuomi Eto, Masato Suzuki, Keisuke Shimizu, Atsuya Niida, Shumpei Hirakawa, Akihiro Toba, Kenji |
author_facet | Saji, Naoki Sakurai, Takashi Ito, Kengo Tomimoto, Hidekazu Kitagawa, Kazuo Miwa, Kaori Tanaka, Yuji Kozaki, Koichi Kario, Kazuomi Eto, Masato Suzuki, Keisuke Shimizu, Atsuya Niida, Shumpei Hirakawa, Akihiro Toba, Kenji |
author_sort | Saji, Naoki |
collection | PubMed |
description | INTRODUCTION: Non-valvular atrial fibrillation (NVAF) is known as a robust risk factor for stroke. Recent reports have suggested a risk of dementia with NVAF, but much remains unknown regarding the relationship between this mechanism and the potential protective effects of novel anticoagulants (direct oral anticoagulants (DOACs), or non-vitamin K oral anticoagulants). METHODS AND ANALYSIS: This study, the strategy to obtain warfarin or DOAC’s benefit by evaluating registry, is an investigator-initiated, multicentre, prospective, observational, longitudinal cohort study comparing the effects of warfarin therapy and DOACs on cerebrovascular diseases and cognitive impairment over an estimated duration of 36 months. Once a year for 3 years, the activities of daily living and cognitive functioning of non-demented patients with NVAF will be assessed. Demographics, risk factors, laboratory investigations, lifestyle, social background and brain MRI will be assessed. ETHICS AND DISSEMINATION: This protocol has been approved by the ethics committee of the National Center for Geriatrics and Gerontology (No. 1017) and complies with the Declaration of Helsinki. Informed consent will be obtained before study enrolment and only coded data will be stored in a secured database. The results will be published in peer-reviewed journals and presented at scientific meetings to ensure the applicability of the findings in clinical practice. TRIAL REGISTRATION NUMBER: UMIN000025721. |
format | Online Article Text |
id | pubmed-6254414 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-62544142018-12-11 Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study) Saji, Naoki Sakurai, Takashi Ito, Kengo Tomimoto, Hidekazu Kitagawa, Kazuo Miwa, Kaori Tanaka, Yuji Kozaki, Koichi Kario, Kazuomi Eto, Masato Suzuki, Keisuke Shimizu, Atsuya Niida, Shumpei Hirakawa, Akihiro Toba, Kenji BMJ Open Neurology INTRODUCTION: Non-valvular atrial fibrillation (NVAF) is known as a robust risk factor for stroke. Recent reports have suggested a risk of dementia with NVAF, but much remains unknown regarding the relationship between this mechanism and the potential protective effects of novel anticoagulants (direct oral anticoagulants (DOACs), or non-vitamin K oral anticoagulants). METHODS AND ANALYSIS: This study, the strategy to obtain warfarin or DOAC’s benefit by evaluating registry, is an investigator-initiated, multicentre, prospective, observational, longitudinal cohort study comparing the effects of warfarin therapy and DOACs on cerebrovascular diseases and cognitive impairment over an estimated duration of 36 months. Once a year for 3 years, the activities of daily living and cognitive functioning of non-demented patients with NVAF will be assessed. Demographics, risk factors, laboratory investigations, lifestyle, social background and brain MRI will be assessed. ETHICS AND DISSEMINATION: This protocol has been approved by the ethics committee of the National Center for Geriatrics and Gerontology (No. 1017) and complies with the Declaration of Helsinki. Informed consent will be obtained before study enrolment and only coded data will be stored in a secured database. The results will be published in peer-reviewed journals and presented at scientific meetings to ensure the applicability of the findings in clinical practice. TRIAL REGISTRATION NUMBER: UMIN000025721. BMJ Publishing Group 2018-11-25 /pmc/articles/PMC6254414/ /pubmed/30478106 http://dx.doi.org/10.1136/bmjopen-2018-021759 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Neurology Saji, Naoki Sakurai, Takashi Ito, Kengo Tomimoto, Hidekazu Kitagawa, Kazuo Miwa, Kaori Tanaka, Yuji Kozaki, Koichi Kario, Kazuomi Eto, Masato Suzuki, Keisuke Shimizu, Atsuya Niida, Shumpei Hirakawa, Akihiro Toba, Kenji Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study) |
title | Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study) |
title_full | Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study) |
title_fullStr | Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study) |
title_full_unstemmed | Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study) |
title_short | Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study) |
title_sort | protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (strawberry study) |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254414/ https://www.ncbi.nlm.nih.gov/pubmed/30478106 http://dx.doi.org/10.1136/bmjopen-2018-021759 |
work_keys_str_mv | AT sajinaoki protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy AT sakuraitakashi protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy AT itokengo protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy AT tomimotohidekazu protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy AT kitagawakazuo protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy AT miwakaori protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy AT tanakayuji protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy AT kozakikoichi protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy AT kariokazuomi protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy AT etomasato protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy AT suzukikeisuke protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy AT shimizuatsuya protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy AT niidashumpei protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy AT hirakawaakihiro protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy AT tobakenji protectiveeffectsoforalanticoagulantsoncerebrovasculardiseasesandcognitiveimpairmentinpatientswithatrialfibrillationprotocolforamulticentreprospectiveobservationallongitudinalcohortstudystrawberrystudy |